Yongxiang Xia

Nanjing University of Chinese Medicine — China

Medicine · Health Sciences

27h-index3.2kcitations83works7.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(14), Cholangiocarcinoma and Gallbladder Cancer Studies(13), Hepatocellular Carcinoma Treatment and Prognosis(12), Pancreatic and Hepatic Oncology Research(11), Immune Cell Function and Interaction(10)

Publications83 total

Radiogenomics predicts immune microenvironment heterogeneity and response to combination immunotherapy in hepatocellular carcinoma
Journal of Translational Medicine·2026Open Access
Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study
Hepatobiliary & pancreatic diseases international·2025
Hexokinase 2-mediated metabolic stress and inflammation burden of liver macrophages via histone lactylation in MASLD
Cell Reports·2025· 9 citedOpen Access
Hexokinase 2-mediated metabolic stress and inflammation burden of liver macrophages via histone lactylation in MASLD
Cell Reports·2025· 16 citedOpen Access
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Clinical and Molecular Hepatology·2025· 5 citedOpen Access
MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing
Cell Death and Disease·2024· 17 citedOpen Access
Metabolomics reveals ascorbic acid inhibits ferroptosis in hepatocytes and boosts the effectiveness of anti-PD1 immunotherapy in hepatocellular carcinoma
Cancer Cell International·2024· 9 citedOpen Access
Differentiation and immunosuppressive function of CD19+CD24hiCD27+ regulatory B cells are regulated through the miR-29a-3p/NFAT5 pathway
Hepatobiliary & pancreatic diseases international·2024· 5 cited
Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study
Journal of Gastrointestinal Oncology·2023· 6 citedOpen Access
Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer·2023· 39 citedOpen Access
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
The Lancet·2023· 418 citedOpen Access
Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma
Journal of Hepatology·2023· 121 citedOpen Access
Effect of different <scp>PD</scp>‐1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma
Alimentary Pharmacology & Therapeutics·2023· 10 cited
Efficacy and safety of IBI110 in combination with sintilimab and lenvatinib in first-line of advanced hepatocellular carcinoma: Preliminary results from a phase Ib study.
Journal of Clinical Oncology·2023· 1 cited
Gsk3β deficiency in macrophages alleviates the progression of nonalcoholic steatohepatitis by promoting PINK1-mediated mitophagic autophagy α β γ
Research Square (Research Square)·2023Open Access
Data from miR-22 Promotes HBV-Related Hepatocellular Carcinoma Development in Males
2023Open Access
Data from miR-22 Promotes HBV-Related Hepatocellular Carcinoma Development in Males
2023Open Access
GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
Journal for ImmunoTherapy of Cancer·2023· 19 citedOpen Access
CRISPR/Cas9 screening reveals that ASB2 inhibits p53-dependent ferroptosis to mediates Lenvatinib resistance in hepatocellular carcinoma
Research Square (Research Square)·2023· 1 citedOpen Access
The Ninj1/Dusp1 Axis Contributes to Liver Ischemia Reperfusion Injury by Regulating Macrophage Activation and Neutrophil Infiltration
Cellular and Molecular Gastroenterology and Hepatology·2023· 39 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Xuehao Wang(23), Weiwei Tang(10), Beicheng Sun(8), Gu‐Wei Ji(7), Xiangcheng Li(7), Haoming Zhou(6), Guangshun Sun(6), Ling Lü(6), Jianhua Rao(6), Guoqiang Sun(6), Runqiu Jiang(5), Xiaofeng Wu(5), Hanyuan Liu(5), Liyong Pu(5), Dawei Rong(5), Xuehao Wang(4), Xiaofeng Qian(4), Feng Cheng(4), Xiangyi Kong(4), Ling Lu(4)